Chronic Hepatitis B
The COBAS AM assay is better suited for detecting low hepatitis B virus levels
Published in Hepatitis Weekly, October 18th, 2004
"The measurement of hepatitis B virus (HBV) DNA is important for the assessment of liver disease and treatment efficacy. Most commercially available assays for the determination of HBV DNA levels have limited linear ranges. This study was performed to evaluate the clinical performance of the Digene Hybrid Capture 11 (Digene HC 11 assay) and the COBAS AMPLICOR Monitor test (COBAS-AM assay), with special emphasis on anti-HBV e antigen (HBeAg)-positive patients with low HBV DNA levels," researchers in the Peoples Republic of China report.
"A total of 425 Chinese patients...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-10-18)
More Articles from Hepatitis Weekly
- Diagnostics
TaqMan hepatitis C virus RNA analyte-specific reagent has wide-ranging uses - Genomics
A new HCV beacon assay more accurately monitors chronic hepatitis C patients - Transplant Medicine
Metabolite assays detect 6-mercaptopurine toxicity after liver transplantation - Vasculitis
Antiviral therapy helps manage polyarteritis nodosa in hepatitis B patients - Virology
Transfected liver cancer cells offer a new venue for exploring hepatitis B - Antiviral Therapy
The p38 signaling pathway influences the response of hepatitis C to interferon - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
